- ANA598 Demonstrates SVR12 In 100% Of First Group Of HCV Patients Randomized To Stop All Treatment At Week 24 July 30, 2010Anadys Pharmaceuticals, Inc. (Nasdaq: ANDS) announced that six of six patients (100%) in the ANA598 200 mg twice daily (bid) arm who were randomized to stop all treatment at Week 24 in an ongoing Phase II trial maintained undetectable levels of virus 12 weeks after stopping treatment, referred to as Sustained Virological Response 12, or SVR12... […]
- Important Information For Patients From Susan G. Komen For The Cure® And The College Of American Pathologists July 30, 2010Recent media reports of potential misdiagnosis of early-stage breast cancer may frighten women away from breast cancer screening that could save their lives. Rather than shying away from screening, women should know the questions to ask and be confident about weighing their options, according to Susan G. Komen for the Cure®, the world's largest breast c […]
Subscribe to this site's RSS feed.